Watching BIOVIE INC.? See every signal: funding, hires, M&A, contracts, sentiment.
Book a demoChoose your planAI Executive Summary
AI-powered analysis of 10-K filing content
BioVie remains a pre-revenue, clinical-stage biopharmaceutical company entirely dependent on the success of its lead candidate bezisterim (NE3107) and its liver disease asset BIV201. The company faces significant going-concern-type risks including need for substantial additional capital, no approved products, and newly disclosed securities class action litigation, while recently reporting topline Phase 2b SUNRISE-PD trial results for Parkinson's disease.
Red Flags Detected (7)
Company is currently subject to securities class action litigation
No products approved for commercial sale and no revenue generated since inception
Concentration of company assets within a single financial institution poses material risk
4 more red flags detected
Key Takeaways
BioVie remains a single-asset-dependent clinical-stage company with bezisterim as its primary value driver across AD, PD, and Long COVID indications
Phase 2b SUNRISE-PD topline results (reported August 2026) are a key near-term catalyst but do not guarantee Phase 3 success or regulatory approval
3 more takeaways
Filing Overview
What This Means
Annual Report: Comprehensive filing covering the full fiscal year with audited financial statements.